Excitement about the potential of artificial intelligence (AI) to transform drug discovery has been building for several years. Millions of dollars have been poured into AI-based drug discovery start-ups in the US, Europe and beyond, who are all racing to reach the first true proof-of-concept for the approach.
Big pharma has also been investing in the field, both internally and in partnership with new AI-focused platforms. There is no doubt that AI in drug discovery has become one...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on In Vivo for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?